Jonas Ristau

<i>EML4‐ALK</i> fusion variant V3 is a high‐risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK⁺ non‐small cell lung cancer

Petros Christopoulos, Volker Endris, Farastuk Bozorgmehr et al. · International Journal of Cancer · 2018 · 137 citations · Full text

Medicine, Oncology, Pathology +17

Identification of a highly lethal V3⁺TP53⁺ subset in ALK⁺ lung adenocarcinoma

Petros Christopoulos, Martina Kirchner, Farastuk Bozorgmehr et al. · International Journal of Cancer · 2018 · 106 citations · Full text

Medicine, Oncology, Pathology +17

FAP imaging in rare cancer entities—first clinical experience in a broad spectrum of malignancies

Katharina Dendl, Rebecca Finck, Frederik L. Giesel et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2021 · 59 citations · Full text

Medicine, Oncology, Radiology +17

Impact of Primary Staging with Fibroblast Activation Protein Specific Enzyme Inhibitor (FAPI)-PET/CT on Radio-Oncologic Treatment Planning of Patients with Esophageal Cancer

Jonas Ristau, Frederik L. Giesel, Matthias F. Haefner et al. · Molecular Imaging and Biology · 2020 · 44 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Impact of FAPI-PET/CT on Target Volume Definition in Radiation Therapy of Locally Recurrent Pancreatic Cancer

Jakob Liermann, Mustafa Syed, Edgar Ben‐Josef et al. · Cancers · 2021 · 43 citations · Full text

Medicine, Nuclear Medicine, Radiology +17